Latest filing published 30 Dec 2022 for Athira Pharma, Inc., €2,018.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Glenna Mileson: trading record in brief
This profile gathers the share dealings of Glenna Mileson in LeonaBio, Inc., where the filings describe the role as finance chief. We count 10 filings; the first trade dates from 18 May 2021 and the latest from 28 December 2022.
On the open market, the record shows 1 purchase worth €134k and 1 sale worth €6,684. The net balance comes to €127k on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 5 share grants and 3 option exercises. Since January 2022: 1 purchase and 1 sale on the market.
Most recently, on 30 December 2022, the filings show an open-market purchase worth €134k in LeonaBio, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Glenna Mileson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 763 shares@ US$2.742.0% of flowCommon StockSEC:0001209191-22-063009:0
- 1,721 shares@ US$7.0611.8% of flowCommon StockSEC:0001209191-22-039342:0
- 3,000 shares@ US$10.6441.0% of flowCommon StockSEC:0001209191-22-024219:0
- 931 shares@ US$12.5114.4% of flowCommon StockSEC:0001209191-22-002218:0
- 1,554 shares@ US$14.4525.6% of flowCommon StockSEC:0001209191-21-039627:0
5 of 5 declarations
